arrow
J

James Nagarajah

Radboud University Medical Center
H指数:36
被引数:4,018

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study

在PROMPT研究中,早期转移性去势抵抗性前列腺癌患者的分子反射测试

2025-10-310
OA
Using TGF-β1 Biology in Radioiodine Refractory Differentiated Thyroid Cancer to Re-establish Sodium Iodide Symporter Expression Using Engineered Mesenchymal Stem Cells as Therapy Vehicles

利用TGF-β1生物学机制,在放射性碘抵抗的分化型甲状腺癌中,通过工程化间充质干细胞作为治疗载体,重新建立钠碘转运体表达。

2025-10-170
PRE
The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study

雄激素阻断对复发性或转移性涎腺导管癌患者中[68Ga]Ga-PSMA-11和[18F]FDG PET摄取的影响:一项前瞻性影像学研究

2025-07-150
OAAI
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

进展性转移性去势抵抗性前列腺癌患者 [177Lu]Lu-PSMA-617的健康相关生活质量、疼痛和症状性骨骼事件 (PSMAfore): 一项开放标签、随机、3期试验

2025-05-260
PRE
Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

纳武利尤单抗3mg/kg和伊匹木单抗1mg/kg(nivo3/ipi1)在分子筛选的患者(pts)中用于治疗转移性去势抵抗性前列腺癌(mCRPC)

2024-09-010
PRE
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

177Lu-PSMA-617与雄激素受体途径抑制剂治疗的变化对紫杉烷初治的进行性转移性去势抵抗性前列腺癌患者 (PSMAfore): 一项3期随机对照试验

LANCET
IF88.5
2024-09-014
PRE
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial
CANCER
IF5.1
2024-06-211
OAAI
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
2024-02-292
PRE
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
2024-02-233
OAAI
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients

TP53功能丧失改变对转移性去势抵抗性前列腺癌患者对PSMA放射配体治疗的反应的影响

2024-01-010
OAAI